Mineralys Therapeutics Adds Two Board Members Ahead of FDA Action Date for Lorundrostat
Mineralys Therapeutics, Inc. (MLYS) has appointed Kristine Peterson and Lonnel Coats to its Board of Directors. The governance changes arrive as the biopharmaceutical company prepares for an upcoming decision from regulatory authorities regarding its lead candidate, lorundrostat.
The leadership additions bring operational experience as the firm positions itself for a potential shift into commercial operations. Lorundrostat targets resistant hypertension through the aldosterone pathway, representing a key developmental milestone for the company's clinical pipeline.
Investors will be watching the Dec. 22 PDUFA target action date, when regulatory decision-makers are scheduled to act on lorundrostat. A approval could allow the company to enter the market for resistant hypertension treatments and transition to commercial drug sales.
Key points
- Mineralys Therapeutics appointed Kristine Peterson and Lonnel Coats to its Board of Directors.
- The company is preparing for a Dec. 22 PDUFA target action date for its drug candidate lorundrostat.
- Lorundrostat is designed to treat resistant hypertension by targeting the aldosterone pathway.
- The board additions strengthen governance ahead of a potential transition to commercial operations.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
Who did Mineralys Therapeutics add to its board?
Mineralys Therapeutics appointed Kristine Peterson and Lonnel Coats to its Board of Directors.
What is the FDA target action date for lorundrostat?
The FDA PDUFA target action date for lorundrostat is Dec. 22.
What condition is lorundrostat designed to treat?
Lorundrostat is designed to treat resistant hypertension by targeting the aldosterone pathway.